You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Automated Electrophysiology Assessment of Drug induced Cardiotoxicity Based on Parallel Noninvasive Nanoelectrode Array

    SBC: CYION TECHNOLOGIES LLC            Topic: NIBIB

    Summary Drug safety issues pose a serious challenge to the health and well being of patients The development of our innovative technology aims to address a significant gap in the in vitro assessment of drug induced cardiotoxicity which is the number one reason for withdrawals of all marketed drugs as well as the premature termination of promising drug development candidates Pressured by the eno ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  2. Skin Microbiome Editing with Fermentation Initiator

    SBC: Surface Bioadvances, Inc.            Topic: NIAMS

    Abstract Acne dysbiosis is defined as microbial imbalance with the over growth of Propionibacterium acnes P acnes in the acne microbiome We have demonstrated that Staphylococcus epidermidis S epidermidis a probiotic bacterium co existed with P acnes in an acne lesion can exploit the carbohydrate fermentation to produce short chain fatty acids SCFAs and rein in the over growth of P ac ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  3. Study of the New HDAC i SW as a Treatment for Alzheimer's Disease and Other Tauopathies

    SBC: Starwise Therapeutics LLC            Topic: NIA

    ABSTRACT Alzheimerandapos s and other tauopathies are medical problems growing to historical proportions that threaten the long term viability of medical care systems world wide Alzheimerandapos s costs today are of the US GDP and growing as the population ages Effective disease modifying treatments have yet to be developed A number of drugs in clinical testing target amyloid but very fe ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  4. Using a novel model of antidepressant efficacy to discover new compounds and personalized treatments.

    SBC: PAX NEUROSCIENCE, INC.            Topic: 102

    The World Health Organization estimates that bymajor depressive disorderMDDwill be the most common cause of disabilityworldwideAlthough approximatelyinAmericans will suffer from MDD during their lifetimemany patients with MDD go undiagnosed in primary care settingsandare incorrectly diagnosed with MDDGiven the substantial medicaleconomic and social costs involved with MDDthere is tremendous need f ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Novel Treatment for Traumatic Brain Injury

    SBC: Epigen Biosciences, Inc.            Topic: 101

    SUMMARY Traumatic brain injury TBI is a leading contributor to death and disability in the USA yet widely effective treatments remain elusive and except for a lengthy program of rehabilitation no effective treatment for TBI is available Therefore there is a critical need in new therapeutic approaches which can maximally preserve brain tissue and facilitate functional recovery after TBI In ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Development of Pirenzepine for HIV SN

    SBC: WinSanTor, Inc.            Topic: 101

    PROJECT SUMMARY Over million people worldwide including million people in the USA are HIV positive HIV associated sensory neuropathy HIV SN is the most frequent neurological manifestation of HIV and is characterized as a distal symmetrical predominantly sensory polyneuropathy HIV SN may represent clinically indistinguishable neuropathies with distinct pathogenesis a distal axona ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  7. Aminomethyl benzamides as novel anti Ebola agents

    SBC: Chicago Biosolutions, Inc.            Topic: NIAID

    Ebola EBOV and Marburg MARV viruses belong to the family Filoviridae and can cause fatal hemorrhagic fevers characterized by widespread tissue destruction with an incubation period of days Because of the safety concerns these viruses are designated as the biosafety level agents Currently there is no effective vaccine or therapeutic treatment against filoviral infection and pathogenes ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Novel therapy for Fragile X syndrome

    SBC: Epigen Biosciences, Inc.            Topic: 101

    PROJECT SUMMARY Fragile X syndromeFXSis the most common inheritable form of cognitive impairment and the leading known genetic cause of autismFXS is caused by the loss of expression of the fragile X mental retardation proteinFMRPA major challenge for FXS research is to develop treatment strategies that improve the intellectual capabilities of patientsDysregulated protein synthesis is widely accept ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  9. A Unified System for Wireless Optogenetics and Brain Microdialysis for Small Molecules Prototype Development and Validation

    SBC: AMUZA, INC            Topic: 101

    PROJECT SUMMARY While optogenetics is well suited for understanding the dynamic activity of neural circuits the first central theme of the NIH BRAIN Initiative PAR its neurochemical impacts remain largely uncharacterized due to a lack of appropriate tools Given that the predominant mode of cellular interactions is neurochemical commercial development of such tools will fulfill the ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  10. SA FasL engineered human islets as a novel product for the treatment of type diabetes

    SBC: FasCure Therapeutics LLC            Topic: NIDDK

    PROJECT SUMMARY Type diabetes T D is a chronic autoimmune disorder that affects of population worldwide Exogenous insulin treatment is the standard of care for T D but often negatively affects the quality of life and is ineffective in preventing recurrent hyperglycemia episodes and chronic complications Recent studies show that human islet allografts can restore long term normoglycemia ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government